Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of primary membranous nephropathy (pMN) according to renal biopsy prior to or during screening
Screening urinary protein-to-creatinine ratio (UPCR) \>= 5 g/g from 24-hour urine collection after best supportive care for \>= 3 months prior to screening or screening UPCR \>= 4 g/g after best supportive care for \>= 6 months prior to screening
eGFR \>= 40 mL/min/1.73m\^2 or qualified endogenous creatinine clearance \>= 40 mL/min/1.73m\^2 based on 24-hour urine collection during screening
You may not be if
Participants with a secondary cause of MN
Pregnancy or breastfeeding
Evidence of \>= 50% reduction in proteinuria during the previous 6 months prior to randomization
Severe renal impairment, including the need for dialysis or renal replacement therapy
Type 1 or 2 diabetes mellitus
Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months prior to or during screening; or cyclophosphamide, tacrolimus, or cyclosporin less than 6 months prior to or during screening
Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude participant participation
Known active infection of any kind or recent major episode of infection
Major surgery requiring hospitalization within the 4 weeks prior to screening
Current active alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to screening
Intolerance or contraindication to study therapies
